- China
- /
- Medical Equipment
- /
- SHSE:688581
A Look At The Fair Value Of Hangzhou AGS MedTech Co., Ltd. (SHSE:688581)
Key Insights
- The projected fair value for HangzhouS MedTech is CN¥82.94 based on 2 Stage Free Cash Flow to Equity
- With CN¥68.45 share price, HangzhouS MedTech appears to be trading close to its estimated fair value
- The average premium for HangzhouS MedTech's competitorsis currently 429%
In this article we are going to estimate the intrinsic value of Hangzhou AGS MedTech Co., Ltd. (SHSE:688581) by taking the expected future cash flows and discounting them to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
See our latest analysis for HangzhouS MedTech
What's The Estimated Valuation?
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥268.3m | CN¥295.1m | CN¥318.2m | CN¥338.3m | CN¥356.0m | CN¥372.0m | CN¥386.7m | CN¥400.6m | CN¥414.0m | CN¥427.1m |
Growth Rate Estimate Source | Est @ 13.12% | Est @ 10.01% | Est @ 7.83% | Est @ 6.30% | Est @ 5.23% | Est @ 4.49% | Est @ 3.96% | Est @ 3.60% | Est @ 3.34% | Est @ 3.16% |
Present Value (CN¥, Millions) Discounted @ 7.6% | CN¥249 | CN¥255 | CN¥255 | CN¥252 | CN¥247 | CN¥239 | CN¥231 | CN¥223 | CN¥214 | CN¥205 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥2.4b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.7%. We discount the terminal cash flows to today's value at a cost of equity of 7.6%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥427m× (1 + 2.7%) ÷ (7.6%– 2.7%) = CN¥9.0b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥9.0b÷ ( 1 + 7.6%)10= CN¥4.3b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥6.7b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of CN¥68.5, the company appears about fair value at a 17% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
The Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at HangzhouS MedTech as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.6%, which is based on a levered beta of 0.926. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for HangzhouS MedTech
- Earnings growth over the past year exceeded the industry.
- Currently debt free.
- Dividends are covered by earnings and cash flows.
- Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
- Annual revenue is forecast to grow faster than the Chinese market.
- Good value based on P/E ratio and estimated fair value.
- No apparent threats visible for 688581.
Looking Ahead:
Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For HangzhouS MedTech, we've compiled three additional factors you should assess:
- Financial Health: Does 688581 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does 688581's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Chinese stock every day, so if you want to find the intrinsic value of any other stock just search here.
Valuation is complex, but we're here to simplify it.
Discover if HangzhouS MedTech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688581
HangzhouS MedTech
Engages in the research, development, production, sale, and service of endoscopic surgery equipment and accessories in China.
Flawless balance sheet with solid track record.
Market Insights
Community Narratives
